Literature DB >> 9578029

Selective amobarbital test for the determination of language function in patients with epilepsy with frontal and posterior temporal brain lesions.

M Hajek1, A Valavanis, Y Yonekawa, R Schiess, A Buck, H G Wieser.   

Abstract

PURPOSE: Selective amobarbital tests with selective temporary inactivation of the left frontal operculum and/or the left parietotemporal cortex were performed in 5 patients with left-hemispheric epileptogenic lesions in or adjacent to classical Broca's and/or Wernicke's area. The aim was to assess language functions in these brain regions before surgery, to tailor the surgery according to the individual functional importance of these brain regions, and to predict postoperative outcome.
METHODS: Amobarbital was injected by transfemoral selective catheterization of the arteries supplying the target areas. Along with neuropsychological and neurological testing during the amobarbital procedure, EEG recordings were performed in all patients, and [99mTc]HMPAO-single photon emission computed tomography (SPECT) in 2 patients.
RESULTS: After the amobarbital injection into the left frontal opercular region, there was no recognizable language dysfunction in 3 patients. In these 3 patients, the lesions in or adjacent to the frontal operculum were completely resected without postoperative language impairment. In the remaining 2 patients, temporary language impairment after the amobarbital injection into the left frontoopercular and Wernicke's region, respectively, suggested language functions in these areas. Surgery was restricted to the left mesiotemporal lobe in 1 patient. In the other patient, the tumor infiltrating the frontal operculum was restrictively resected. Postoperatively, the first patient had no language impairment, but the latter had transient global aphasia, from which she recovered.
CONCLUSIONS: Selective temporary amobarbital inactivation of brain regions that may be associated with language has clearly indicated the presence or absence of language functions in these regions. The test contributed substantially to planning of the surgical approach in each patient. The predictive value of the amobarbital test was demonstrated by the postoperative outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578029     DOI: 10.1111/j.1528-1157.1998.tb01391.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  6 in total

1.  Tailored cognitive testing with provocative amobarbital injection preceding AVM embolization.

Authors:  Lauren R Moo; Kieran J Murphy; Philippe Gailloud; Mark Tesoro; John Hart
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

2.  Selective and superselective angiography of pediatric moyamoya disease angioarchitecture in the posterior circulation.

Authors:  Gerasimos Baltsavias; Nadia Khan; Venko Filipce; Anton Valavanis
Journal:  Interv Neuroradiol       Date:  2014-08-28       Impact factor: 1.610

3.  Selective and superselective angiography of pediatric moyamoya disease angioarchitecture: the anterior circulation.

Authors:  Gerasimos Baltsavias; Anton Valavanis; Venko Filipce; Nadia Khan
Journal:  Interv Neuroradiol       Date:  2014-08-28       Impact factor: 1.610

4.  UniversitätsSpital Zürich: 80 years of neurosurgical patient care in Switzerland.

Authors:  Martin N Stienen; Carlo Serra; Lennart H Stieglitz; Niklaus Krayenbühl; Oliver Bozinov; Luca Regli
Journal:  Acta Neurochir (Wien)       Date:  2017-11-13       Impact factor: 2.216

5.  Roles of the Wada Test and Functional Magnetic Resonance Imaging in Identifying the Language-dominant Hemisphere among Patients with Gliomas Located near Speech Areas.

Authors:  Tatsuya Ishikawa; Yoshihiro Muragaki; Takashi Maruyama; Kayoko Abe; Takakazu Kawamata
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-12-15       Impact factor: 1.742

6.  Determination of language areas in patients with epilepsy using the super-selective Wada test.

Authors:  Kazuo Kakinuma; Shin-Ichiro Osawa; Hiroaki Hosokawa; Marie Oyafuso; Shoko Ota; Erena Kobayashi; Nobuko Kawakami; Kazushi Ukishiro; Kazutaka Jin; Makoto Ishida; Takafumi Sato; Mika Sakamoto; Kuniyasu Niizuma; Teiji Tominaga; Nobukazu Nakasato; Kyoko Suzuki
Journal:  IBRO Neurosci Rep       Date:  2022-08-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.